Ivy Song

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 322 citations · Full text

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 295 citations

Week Results, Treatment And Prevention, Antiviral Drug Development +7

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

Sherene Min, Ivy Song, Julie Borland et al. · Antimicrobial Agents and Chemotherapy · 2009 · 239 citations · Full text

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Sherene Min, Louis Sloan, Edwin DeJesus et al. · AIDS · 2011 · 212 citations

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

Kelly E. Dooley, Patrick Sayre, Julie Borland et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 191 citations